LIDDS AB (publ) (LIDDS.ST)

6.99 +0.39 (+5.91%) At close: 05:24PM CEST

LIDDS AB (publ)

Virdings allé 32b
Uppsala 754 50
Sweden
46 00 44 55 66
https://www.liddspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Nina Herne Ph.D.	Chief Exec. Officer	2.2M	N/A	1969
Ms. Monica Wallter	Sr. Advisor	1.87M	N/A	1956
Ms. Jenni Bjornulfson	CFO & Head of IR	N/A	N/A	1971
Mr. Matthew Lindon	Chief Scientific Officer	N/A	N/A	1973
Dr. Johan Harmenberg M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1954

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.

Corporate governance

LIDDS AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.